Biogen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Biogen wird ein jährliches Gewinn- und Umsatzwachstum von 12.4% bzw. 1.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.1% betragen.

Wichtige Informationen

12.4%

Wachstumsrate der Gewinne

14.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	26.7%
Wachstumsrate der Einnahmen	1.3%
Zukünftige Eigenkapitalrendite	13.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16

Recent updates

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BIIB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	9,690	2,403	2,574	2,999	27
12/31/2025	9,526	2,132	2,402	2,789	33
12/31/2024	9,641	1,791	2,082	2,499	33
9/30/2024	9,608	1,615	1,768	2,127	N/A
6/30/2024	9,672	1,159	1,571	1,784	N/A
3/31/2024	9,663	1,167	1,284	1,645	N/A
12/31/2023	9,836	1,161	1,236	1,547	N/A
9/30/2023	9,993	1,462	1,026	1,360	N/A
6/30/2023	9,972	2,665	1,123	1,428	N/A
3/31/2023	10,105	3,131	1,421	1,678	N/A
12/31/2022	10,173	3,047	1,141	1,384	N/A
9/30/2022	10,363	2,865	2,173	2,398	N/A
6/30/2022	10,634	2,059	2,315	2,542	N/A
3/31/2022	10,820	1,450	2,773	3,033	N/A
12/31/2021	10,982	1,556	3,345	3,640	N/A
9/30/2021	11,101	1,546	2,107	2,435	N/A
6/30/2021	11,698	1,918	2,461	2,810	N/A
3/31/2021	12,604	3,012	3,149	3,532	N/A
12/31/2020	13,445	4,001	3,678	4,230	N/A
9/30/2020	14,263	5,082	5,841	6,557	N/A
6/30/2020	14,487	5,927	6,349	7,071	N/A
3/31/2020	14,422	5,879	6,282	7,086	N/A
12/31/2019	14,378	5,889	6,409	7,079	N/A
9/30/2019	14,233	5,396	6,384	7,014	N/A
6/30/2019	14,072	5,294	6,324	7,055	N/A
3/31/2019	13,812	4,667	5,382	6,190	N/A
12/31/2018	13,453	4,431	5,302	6,188	N/A
9/30/2018	13,234	3,187	4,855	5,811	N/A
6/30/2018	12,872	2,968	N/A	5,703	N/A
3/31/2018	12,594	2,964	N/A	5,773	N/A
12/31/2017	12,274	2,539	N/A	4,551	N/A
9/30/2017	11,839	3,486	N/A	4,615	N/A
6/30/2017	11,717	3,293	N/A	3,978	N/A
3/31/2017	11,533	3,480	N/A	3,807	N/A
12/31/2016	11,449	3,703	N/A	4,587	N/A
9/30/2016	11,416	3,885	N/A	4,046	N/A
6/30/2016	11,238	3,818	N/A	3,950	N/A
3/31/2016	10,936	3,695	N/A	3,999	N/A
12/31/2015	10,764	3,547	N/A	3,919	N/A
9/30/2015	10,565	3,599	N/A	3,609	N/A
6/30/2015	10,299	3,490	N/A	3,627	N/A
3/31/2015	10,128	3,277	N/A	3,570	N/A
12/31/2014	9,703	2,935	N/A	2,942	N/A
9/30/2014	9,028	2,509	N/A	2,878	N/A
6/30/2014	8,345	2,139	N/A	2,636	N/A
3/31/2014	7,647	1,916	N/A	2,271	N/A
12/31/2013	6,932	1,862	N/A	2,345	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIIBDas prognostizierte Gewinnwachstum (12.4% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: BIIBDie Erträge des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).

Hohe Wachstumserträge: BIIBDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BIIBDie Einnahmen des Unternehmens (1.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: BIIBDie Einnahmen des Unternehmens (1.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIIBDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.1%).

Biogen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates increase by 11%

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Recent updates

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Stock: Cheapish, But With Few Growth Prospects

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Gewinn- und Umsatzwachstumsprognosen